Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Theravance Biopharma, Inc.NASDAQ: TBPH

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures outflow grows to $0

Q1 FY2026 capital expenditures was $0, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$42K. Over 3 fiscal years it compounded at -58.1% a year.

Context

  • Capital expenditures amounted to 0.0% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$10.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$42K-87.3% YoY
LTMMar 2026
-$42K-82.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-87.3%——
3-year CAGR-58.1%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(42K) USD
Year-over-year change
+87.3%

Capital Expenditures vs competitors

How TBPH compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -82.6% is the 6th highest of 8, against a peer median of -26.6%.
  • Capital expenditures amounts to 0.0% of revenue for TBPH, versus a peer median of 2.2%.
TBPH Competitors
Capital Expenditures for TBPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REPLReplimune Group, Inc.LTM Dec 2025$5.35M USD-26.6%+42.0%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$4.98M USD+18.8%-28.6%11.6%
VALNValneva SELTM Mar 2026€3.42M EUR-83.6%-46.5%2.2%
VIRVir Biotechnology, Inc.LTM Mar 2026$1.24M USD+117.6%-58.6%1.9%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$735K USD+27.2%-49.9%3.5%
GERNGeron CorporationLTM Mar 2026$333K USD-100.7%-51.6%0.2%
TYRATyra Biosciences, Inc.LTM Mar 2026$215K USD-60.3%-36.8%—
TBPHTheravance Biopharma, Inc.LTM Mar 2026$42K USD-82.6%-58.1%0.0%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding TBPH) —-26.6%-46.5%2.2%

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(265.07M)(92.82M)(55.19M)(56.42M)105.9M
Depreciation & Amortization8.6M7.02M4.26M3.62M5.64M
Deferred Income Tax003.21M(7.57M)(11.52M)
Stock-Based Compensation62.06M39.73M25.37M21.39M18.48M
Change in Working Capital(39.55M)42.35M(8.34M)20.36M120.47M
Accounts Receivables1.8M(2.72M)(689K)(966K)(27.1M)
Inventory00000
Accounts Payables(3.53M)(1.61M)6K750K326K
Other Working Capital(37.82M)46.68M(7.66M)20.57M147.24M
Other Non-Cash Items26.1M(183.28M)3.7M7.09M(423K)
Operating Cash Flow(207.86M)(186.99M)(27M)(11.54M)238.54M
Capital Expenditures(3.41M)(572K)(2.49M)(332K)(42K)
Acquisitions (Net)00000
Purchases of Investments(158.31M)(103.15M)(134.53M)(143.04M)(248.22M)
Sales of Investments286.2M158.02M102.81M155.65M142.98M
Other Investing Activities6K1.1B1.51M00
Investing Cash Flow124.49M1.15B(32.7M)12.28M(105.28M)
Debt Repayment(10.73M)(631.6M)000
Common Stock Issued108.18M0099K786K
Common Stock Repurchased(9.06M)(132.28M)(199.55M)(3.1M)(4.03M)
Dividends Paid00000
Other Financing Activities3.47M5.08M618K508K0
Financing Cash Flow91.86M(758.81M)(198.93M)(2.5M)(3.25M)
Effect of Forex Changes00000
Net Change in Cash8.5M208.21M(258.63M)(1.75M)130.01M
Free Cash Flow(211.26M)(187.56M)(29.49M)(11.87M)238.5M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.